Harrow registers Phase 3 trial of TRIESENCE for pain and inflammation after eye surgery
Harrow Inc's Phase 3 study of subconjunctival TRIESENCE injections in cataract surgery patients is enrolling by invitation, aiming to support an sNDA.
Harrow Inc has one new registry entry this week for a late-stage ophthalmic trial.
- Harrow Inc's Phase 3 trial (NCT07832552) is testing TRIESENCE, triamcinolone acetonide injectable suspension, given as a 100 µL subconjunctival injection for the treatment of ocular inflammation and pain after ophthalmic surgery.1 The study is enrolling by invitation, with about 250 subjects planned across 16 sites, and total subject participation of about 120 days including screening, surgery, postoperative follow-up through Day 90, and a possible safety follow-up to Day 1201, and the trial is designed to support a supplemental New Drug Application.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.